Alpa Laboratories Declares Q3 FY26 Standalone & Consolidated Financial Results
Alpa Laboratories announced its Q3 FY26 results. For the quarter ended December 31, 2025, standalone profit after tax was ₹0.19 crore on revenue of ₹29.93 crore. Consolidated profit after tax was also ₹0.19 crore on revenue of ₹29.96 crore. For the nine months ended December 31, 2025, standalone profit after tax was ₹13.75 crore.
The announcement of quarterly financial results is a material event for investors and stakeholders. The reported figures, while not drastically different from previous periods, provide essential information for investment decisions and market analysis.
The financial results for the quarter and nine months ended December 31, 2025, show a mixed performance with a slight profit in the quarter but a significant profit for the nine-month period. The results are largely in line with expectations and do not present a major positive or negative surprise.
Alpa Laboratories Limited announced the outcome of its Board Meeting held on February 11, 2026. The Board approved the Un-Audited Standalone & Consolidated Financial Results for the quarter ended December 31, 2025, along with the Limited Review Report from the Statutory Auditor.
The meeting commenced at 11:00 AM and concluded at 12:05 PM at the Company's registered office in Indore.
For the quarter ended December 31, 2025, the standalone results show total income from operations at ₹29.93 crore and a profit after tax of ₹0.19 crore. The consolidated results for the same period indicate total income from operations at ₹29.96 crore and a profit after tax of ₹0.19 crore.
For the nine months ended December 31, 2025, standalone revenue from operations stood at ₹90.32 crore, with a profit after tax of ₹13.75 crore. On a consolidated basis, revenue from operations for the nine months was ₹90.33 crore, and profit after tax was ₹13.78 crore.
What to do with a filing like this
Alpa Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alpa Laboratories Limited. Read the original for the full detail.